Search Results

You are looking at 151 - 160 of 1,243 items for :

  • Refine by Access: All x
Clear All
Full access

Mandy R. Sakamoto, Megan Eguchi, Christine M. Azelby, Jennifer R. Diamond, Christine M. Fisher, Virginia F. Borges, Cathy J. Bradley, and Peter Kabos

prescribing opioids in patients with cancer focus on relieving acute pain or pain associated with advanced disease. 13 – 16 A recent study of patients with cancer undergoing curative-intent surgery found that 10.4% had new persistent opioid use at 1 year

Full access

Stephen B. Edge and David G. Sheldon

findings from the National Surgical Adjuvant Breast Project (protocol 6). I. Intraductal carcinoma (DCIS) . Cancer 1986 ; 57 : 197 – 208 . 12 Solin LJ Kurtz J Fourquet A . Fifteen-year results of breast-conserving surgery and definitive

Full access

Presenter: Stephen W. Behrman

, Stephen W. Behrman, MD, Professor of Surgery, The University of Tennessee Health Science Center, highlighted the presentation and clinical evaluation of ampullary adenocarcinoma, discussed current management and outcomes, and introduced the inaugural 2022

Full access

Rodger J. Winn

References 1 Vender JR Miller J Rekito A : Effect of hemostasis and electrosurgery in the development and evolution of brain tumor surgery in the late 19 th and 20 th century . Neurosurg Focus 2005 ; 18 : 1 - 7 . 2

Full access

Scott M. Gilbert and Brent K. Hollenbeck

prospective long-term follow-up study . Surgery 1998 ; 123 : 573 – 578 . 21 Igaki H Tachimori Y Kato H . Improved survival for patients with upper and/or middle mediastinal lymph node metastases of squamous cell carcinoma of the lower thoracic

Full access

Alvin R. Cabrera, Kyle C. Cuneo, James J. Vredenburgh, John H. Sampson, and John P. Kirkpatrick

bevacizumab, followed by temozolomide, bevacizumab, and irinotecan (CPT-11). Four weeks after surgery, he began radiotherapy (volumetric modulated arc therapy), receiving 50.4 Gy to the left frontoparietal region with a 9-Gy boost to the tumor bed over 6

Full access

Alimujiang Wushou, Meng Wang, Feiluore Yibulayin, Lei Feng, Meng-meng Lu, Yuan Luo, Hui Liu, and Zhi-cheng Yang

Oncology (NCCN Guidelines) for Head and Neck Cancers, 2 surgery is the primary treatment modality for all stages of OSCC, whereas the addition of adjuvant therapeutic regimens, including radiation therapy and chemotherapy, and the use of targeted

Full access

Jeffrey F. Moley

confirm the indolent nature of the disease and suggest the benefit of therapeutic interventions that keep tumor burden at a minimum (reoperative surgery when technically possible, cytostatic agents, selective use of external-beam radiation therapy [EBRT

Full access

Michael B. Streiff, Bjorn Holmstrom, Dana Angelini, Aneel Ashrani, Amro Elshoury, John Fanikos, Kleber Yotsumoto Fertrin, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Krishna Gundabolu, Ibrahim Ibrahim, Eric Kraut, Andrew D. Leavitt, Alfred Lee, Jason T. Lee, Ming Lim, Janelle Mann, Karlyn Martin, Brandon McMahon, John Moriarty, Colleen Morton, Thomas L. Ortel, Rita Paschal, Jordan Schaefer, Sanford Shattil, Tanya Siddiqi, Deepak Sudheendra, Eliot Williams, Liz Hollinger, and Mai Q. Nguyen

cancer patients by 2- to 6-fold. 8 – 12 VTE has been reported to be the most common cause of death at 30-day follow-up among cancer patients undergoing surgery. 13 Thus, cancer-associated VTE is a critical concern for oncology patients and healthcare

Full access

Stephanie A. Terezakis and Nancy Y. Lee

invasive cancer not presenting until 20 to 30 years of age. 10 , 11 Genetic screening should be performed for all patients presenting with MTC because surgery for early-stage disease is curative. 8 , 13 – 16 Before surgery, patients must undergo